1-20 of 23
Egbert F. Smit
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol

Karlijn Verkerk, Tijmen J.W.T. van der Wel, Laurien J. Zeverijn, Birgit S. Geurts, Ilse A.C. Spiekman, Gijs F. de Wit, Paul Roepman, Anne M.L. Jansen, Vincent van der Noort, Egbert F. Smit, Ann Hoeben, Lizza E.L. Hendriks, Michel M. van den Heuvel, Berber Piet, Gerarda J.M. Herder, Sayed M.S. Hashemi, Hans Gelderblom, Henk M.W. Verheul, Emile E. Voest, Adrianus J. de Langen
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (23): 5323–5332.
https://doi.org/10.1158/1078-0432.CCR-24-1925
Published: 02 December 2024
View article titled, Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol
Open the PDF for Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol in another window
Includes: Supplementary data
Journal Articles

Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer

Joris van de Haar, Joanne M. Mankor, Karlijn Hummelink, Kim Monkhorst, Egbert F. Smit, Lodewyk F.A. Wessels, Edwin Cuppen, Joachim G.J.V. Aerts, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (7): 1307–1318.
https://doi.org/10.1158/1078-0432.CCR-23-4027
Published: 01 April 2024
View article titled, Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
Open the PDF for Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics

Karlijn Hummelink, Renaud Tissier, Linda J.W. Bosch, Oscar Krijgsman, Michel M. van den Heuvel, Willemijn S.M.E. Theelen, Diane Damotte, François Goldwasser, Karen Leroy, Egbert F. Smit, Gerrit A. Meijer, Daniela S. Thommen, Kim Monkhorst
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 814–823.
https://doi.org/10.1158/1078-0432.CCR-23-1061
Published: 16 February 2024
View article titled, A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Open the PDF for A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics in another window
Includes: Supplementary data
Journal Articles

PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC

Karlijn Hummelink, Vincent van der Noort, Mirte Muller, Robert D. Schouten, Ferry Lalezari, Dennis Peters, Willemijn S.M.E. Theelen, Viktor H. Koelzer, Kirsten D. Mertz, Alfred Zippelius, Michel M. van den Heuvel, Annegien Broeks, John B.A.G. Haanen, Ton N. Schumacher, Gerrit A. Meijer, Egbert F. Smit, Kim Monkhorst, Daniela S. Thommen
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (22): 4893–4906.
https://doi.org/10.1158/1078-0432.CCR-22-0992
Published: 14 November 2022
View article titled, PD-1<sup>T</sup> TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
Open the PDF for PD-1<sup>T</sup> TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC in another window
Includes: Supplementary data
Journal Articles

Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

Louisa R. Hoes, Jade M. van Berge Henegouwen, Hanneke van der Wijngaart, Laurien J. Zeverijn, Daphne L. van der Velden, Joris van de Haar, Paul Roepman, Wendy J. de Leng, Anne M.L. Jansen, Erik van Werkhoven, Vincent van der Noort, Alwin D.R. Huitema, Eelke H. Gort, Jan Willem B. de Groot, Emile D. Kerver, Derk Jan de Groot, Frans Erdkamp, Laurens V. Beerepoot, Mathijs P. Hendriks, Egbert F. Smit, Winette T.A. van der Graaf, Carla M.L. van Herpen, Mariette Labots, Ann Hoeben, Hans Morreau, Martijn P. Lolkema, Edwin Cuppen, Hans Gelderblom, Henk M.W. Verheul, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1402–1411.
https://doi.org/10.1158/1078-0432.CCR-21-3752
Published: 01 April 2022
View article titled, Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
Open the PDF for Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment in another window
Includes: Supplementary data
Journal Articles

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

Xiuning Le, Hiroshi Sakai, Enriqueta Felip, Remi Veillon, Marina Chiara Garassino, Jo Raskin, Alexis B. Cortot, Santiago Viteri, Julien Mazieres, Egbert F. Smit, Michael Thomas, Wade T. Iams, Byoung Chul Cho, Hye Ryun Kim, James Chih-Hsin Yang, Yuh-Min Chen, Jyoti D. Patel, Christine M. Bestvina, Keunchil Park, Frank Griesinger, Melissa Johnson, Maya Gottfried, Christian Britschgi, John Heymach, Elif Sikoglu, Karin Berghoff, Karl-Maria Schumacher, Rolf Bruns, Gordon Otto, Paul K. Paik
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (6): 1117–1126.
https://doi.org/10.1158/1078-0432.CCR-21-2733
Published: 15 March 2022
View article titled, Tepotinib Efficacy and Safety in Patients with <em>MET</em> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
Open the PDF for Tepotinib Efficacy and Safety in Patients with <em>MET</em> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice in another window
Includes: Supplementary data
Journal Articles

A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors

Mirte Muller, Karlijn Hummelink, Daan P. Hurkmans, Anna-Larissa N. Niemeijer, Kim Monkhorst, Joanna Roder, Carlos Oliveira, Heinrich Roder, Joachim G. Aerts, Egbert F. Smit
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (19): 5188–5197.
https://doi.org/10.1158/1078-0432.CCR-20-0538
Published: 01 October 2020
View article titled, A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors
Open the PDF for A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors in another window
Includes: Supplementary data
Journal Articles

Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non–small Cell Lung Cancer Patients

Pauline L. de Goeje, Myrthe Poncin, Koen Bezemer, Margaretha E.H. Kaijen-Lambers, Harry J.M. Groen, Egbert F. Smit, Anne-Marie C. Dingemans, André Kunert, Rudi W. Hendriks, Joachim G.J.V. Aerts
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (7): 2219–2227.
https://doi.org/10.1158/1078-0432.CCR-18-2243
Published: 01 April 2019
View article titled, Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non–small Cell Lung Cancer Patients
Open the PDF for Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non–small Cell Lung Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome

Jules L. Derks, Noémie Leblay, Erik Thunnissen, Robert Jan van Suylen, Michael den Bakker, Harry J.M. Groen, Egbert F. Smit, Ronald Damhuis, Esther C. van den Broek, Amélie Charbrier, Matthieu Foll, James D. McKay, Lynnette Fernandez-Cuesta, Ernst-Jan M. Speel, Anne-Marie C. Dingemans
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (1): 33–42.
https://doi.org/10.1158/1078-0432.CCR-17-1921
Published: 02 January 2018
View article titled, Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome
Open the PDF for Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome in another window
Includes: Supplementary data
Journal Articles

Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography

Astrid A.M. van der Veldt, Mark Lubberink, Ron H.J. Mathijssen, Walter J. Loos, Gerarda J.M. Herder, Henri N. Greuter, Emile F.I. Comans, Hugo B. Rutten, Jonas Eriksson, Albert D. Windhorst, N. Harry Hendrikse, Pieter E. Postmus, Egbert F. Smit, Adriaan A. Lammertsma
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (15): 4163–4173.
https://doi.org/10.1158/1078-0432.CCR-12-3779
Published: 31 July 2013
View article titled, Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [<sup>11</sup>C]docetaxel and Positron Emission Tomography
Open the PDF for Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [<sup>11</sup>C]docetaxel and Positron Emission Tomography in another window
Includes: Supplementary data
Journal Articles

A Phase II Study of Sorafenib in Patients with Platinum-Pretreated, Advanced (Stage IIIb or IV) Non–Small Cell Lung Cancer with a KRAS Mutation

Anne-Marie C. Dingemans, Wouter W. Mellema, Harry J.M. Groen, Atie van Wijk, Sjaak A. Burgers, Peter W.A. Kunst, Erik Thunnissen, Danielle A.M. Heideman, Egbert F. Smit
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (3): 743–751.
https://doi.org/10.1158/1078-0432.CCR-12-1779
Published: 31 January 2013
View article titled, A Phase II Study of Sorafenib in Patients with Platinum-Pretreated, Advanced (Stage IIIb or IV) Non–Small Cell Lung Cancer with a <em>KRAS</em> Mutation
Open the PDF for A Phase II Study of Sorafenib in Patients with Platinum-Pretreated, Advanced (Stage IIIb or IV) Non–Small Cell Lung Cancer with a <em>KRAS</em> Mutation in another window
Journal Articles

Development of [11C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status

Idris Bahce, Egbert F. Smit, Mark Lubberink, Astrid A. M. van der Veldt, Maqsood Yaqub, Albert D. Windhorst, Robert C. Schuit, Erik Thunnissen, Daniëlle A. M. Heideman, Pieter E. Postmus, Adriaan A. Lammertsma, N. Harry Hendrikse
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (1): 183–193.
https://doi.org/10.1158/1078-0432.CCR-12-0289
Published: 02 January 2013
View article titled, Development of [<sup>11</sup>C]erlotinib Positron Emission Tomography for <em>In Vivo</em> Evaluation of EGF Receptor Mutational Status
Open the PDF for Development of [<sup>11</sup>C]erlotinib Positron Emission Tomography for <em>In Vivo</em> Evaluation of EGF Receptor Mutational Status in another window
Includes: Supplementary data
Journal Articles

Abstract PR5: A phase II study of sorafenib in patients with stage IV non-small cell lung cancer (NSCLC) with a K-Ras mutation

Wouter W. Mellema, Anne-Marie C. Dingemans, Harry J.M. Groen, Atie van Wijk, Sjaak Burgers, Peter W.A. Kunst, Frederik B. Thunnissen, Daniëlle A.M. Heideman, Egbert F. Smit
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (3_Supplement): PR5.
https://doi.org/10.1158/1078-0432.12AACRIASLC-PR5
Published: 01 February 2012
View article titled, Abstract PR5: A phase II study of sorafenib in patients with stage IV non-small cell lung cancer (NSCLC) with a K-Ras mutation
Open the PDF for Abstract PR5: A phase II study of sorafenib in patients with stage IV non-small cell lung cancer (NSCLC) with a K-Ras mutation in another window
Journal Articles

Abstract A31: Predictive and prognostic value of KRAS mutations in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy

Wouter W. Mellema, Anne-Marie C. Dingemans, Egbert F. Smit, Jules Derks, Daniëlle A.M. Heideman, Robertjan van Suylen, Frederik B. Thunnissen
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (3_Supplement): A31.
https://doi.org/10.1158/1078-0432.12AACRIASLC-A31
Published: 01 February 2012
View article titled, Abstract A31: Predictive and prognostic value of KRAS mutations in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy
Open the PDF for Abstract A31: Predictive and prognostic value of KRAS mutations in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy in another window
Journal Articles

Absolute Quantification of [11C]docetaxel Kinetics in Lung Cancer Patients Using Positron Emission Tomography

Astrid A.M. van der Veldt, Mark Lubberink, Henri N. Greuter, Emile F.I. Comans, Gerarda J.M. Herder, Maqsood Yaqub, Robert C. Schuit, Arthur van Lingen, S. Nafees Rizvi, Martien P.J. Mooijer, Anneloes Y. Rijnders, Albert D. Windhorst, Egbert F. Smit, N. Harry Hendrikse, Adriaan A. Lammertsma
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (14): 4814–4824.
https://doi.org/10.1158/1078-0432.CCR-10-2933
Published: 17 July 2011
View article titled, Absolute Quantification of [<sup>11</sup>C]docetaxel Kinetics in Lung Cancer Patients Using Positron Emission Tomography
Open the PDF for Absolute Quantification of [<sup>11</sup>C]docetaxel Kinetics in Lung Cancer Patients Using Positron Emission Tomography in another window
Journal Articles

A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer

Joline S.W. Lind, Anne-Marie C. Dingemans, Harry J.M. Groen, Frederik B. Thunnissen, Otto Bekers, Daniëlle A.M. Heideman, Richard J. Honeywell, Elisa Giovannetti, Godefridus J. Peters, Pieter E. Postmus, Robert Jan van Suylen, Egbert F. Smit
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (11): 3078–3087.
https://doi.org/10.1158/1078-0432.CCR-09-3033
Published: 31 May 2010
View article titled, A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer
Open the PDF for A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer in another window
Journal Articles

An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non–Small-Cell Lung Cancer

Paul Roepman, Jacek Jassem, Egbert F. Smit, Thomas Muley, Jacek Niklinski, Tony van de Velde, Anke T. Witteveen, Witold Rzyman, Arno Floore, Sjaak Burgers, Giuseppe Giaccone, Michael Meister, Hendrik Dienemann, Marcin Skrzypski, Miroslaw Kozlowski, Wolter J. Mooi, Nico van Zandwijk
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (1): 284–290.
https://doi.org/10.1158/1078-0432.CCR-08-1258
Published: 31 December 2008
View article titled, An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non–Small-Cell Lung Cancer
Open the PDF for An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non–Small-Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

A Parallel Dose-Escalation Study of Weekly and Twice-Weekly Bortezomib in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced Solid Tumors

Jens Voortman, Egbert F. Smit, Richard Honeywell, Bart C. Kuenen, Godefridus J. Peters, Helgi van de Velde, Giuseppe Giaccone
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (12): 3642–3651.
https://doi.org/10.1158/1078-0432.CCR-07-0061
Published: 15 June 2007
View article titled, A Parallel Dose-Escalation Study of Weekly and Twice-Weekly Bortezomib in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced Solid Tumors
Open the PDF for A Parallel Dose-Escalation Study of Weekly and Twice-Weekly Bortezomib in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced Solid Tumors in another window
Journal Articles

The Natural Course of Preneoplastic Lesions in Bronchial Epithelium

Roderick H. Breuer, Arifa Pasic, Egbert F. Smit, Esther van Vliet, Anton Vonk Noordegraaf, Elle J. Risse, Pieter E. Postmus, Thomas G. Sutedja
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (2): 537–543.
https://doi.org/10.1158/1078-0432.537.11.2
Published: 08 February 2005
View article titled, The Natural Course of Preneoplastic Lesions in Bronchial Epithelium
Open the PDF for The Natural Course of Preneoplastic Lesions in Bronchial Epithelium in another window
Journal Articles

European Organization for Research and Treatment of Cancer (EORTC) 08957 Phase II Study of Topotecan in Combination with Cisplatin as Second-Line Treatment of Refractory and Sensitive Small Cell Lung Cancer

Andrea Ardizzoni, Christian Manegold, Channa Debruyne, Rabab Gaafar, Erika Buchholz, Egbert F. Smit, Pilar Lianes, Guul ten Velde, Lionel Bosquee, Catherine Legrand, Carlo Neumaier, Kathrine King, Giuseppe Giaccone for the EORTC Lung Cancer Group
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (1): 143–150.
Published: 01 January 2003
View article titled, European Organization for Research and Treatment of Cancer (EORTC) 08957 Phase II Study of Topotecan in Combination with Cisplatin as Second-Line Treatment of Refractory and Sensitive Small Cell Lung Cancer
Open the PDF for European Organization for Research and Treatment of Cancer (EORTC) 08957 Phase II Study of Topotecan in Combination with Cisplatin as Second-Line Treatment of Refractory and Sensitive Small Cell Lung Cancer in another window